HRP20110035T1 - Memantin za liječenje blage-do-umjerene alzheimer-ove bolesti - Google Patents

Memantin za liječenje blage-do-umjerene alzheimer-ove bolesti Download PDF

Info

Publication number
HRP20110035T1
HRP20110035T1 HR20110035T HRP20110035T HRP20110035T1 HR P20110035 T1 HRP20110035 T1 HR P20110035T1 HR 20110035 T HR20110035 T HR 20110035T HR P20110035 T HRP20110035 T HR P20110035T HR P20110035 T1 HRP20110035 T1 HR P20110035T1
Authority
HR
Croatia
Prior art keywords
day
memantine
mild
disease
moderate alzheimer
Prior art date
Application number
HR20110035T
Other languages
English (en)
Croatian (hr)
Inventor
Mcdonald Scott
Gergel Ivan
St�ffler Albrecht
Moebius Hans-Joerg
Wirth Yvonne
Potkin Steven
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34798833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110035(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Publication of HRP20110035T1 publication Critical patent/HRP20110035T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
HR20110035T 2004-01-05 2011-01-18 Memantin za liječenje blage-do-umjerene alzheimer-ove bolesti HRP20110035T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53455304P 2004-01-05 2004-01-05
US54217604P 2004-02-04 2004-02-04
PCT/US2005/000145 WO2005067908A2 (en) 2004-01-05 2005-01-05 Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease

Publications (1)

Publication Number Publication Date
HRP20110035T1 true HRP20110035T1 (hr) 2011-02-28

Family

ID=34798833

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110035T HRP20110035T1 (hr) 2004-01-05 2011-01-18 Memantin za liječenje blage-do-umjerene alzheimer-ove bolesti

Country Status (17)

Country Link
US (2) US20060020042A1 (ru)
EP (1) EP1703902B1 (ru)
AT (1) ATE486592T1 (ru)
AU (1) AU2005204358B2 (ru)
CA (1) CA2551689A1 (ru)
CY (1) CY1111359T1 (ru)
DE (1) DE602005024511D1 (ru)
DK (1) DK1703902T3 (ru)
HR (1) HRP20110035T1 (ru)
IL (1) IL176689A0 (ru)
NZ (1) NZ548327A (ru)
PL (1) PL1703902T3 (ru)
PT (1) PT1703902E (ru)
RS (1) RS51540B (ru)
RU (1) RU2371173C2 (ru)
SI (1) SI1703902T1 (ru)
WO (1) WO2005067908A2 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
KR20090047391A (ko) * 2006-04-07 2009-05-12 데벨로겐 악틴게젤샤프트 약제학적 조성물을 위한 Ｍｎｋ1/Ｍｎｋ2 억제 활성을 갖는티에노피리미딘
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2056876A1 (en) * 2006-08-21 2009-05-13 Novartis AG Biomarkers for alzheimer's disease progression
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
AU2009286734A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
TWI517850B (zh) 2009-09-30 2016-01-21 Ｖｔｖ治療有限責任公司 經取代之咪唑衍生物及其使用方法
EA201201191A1 (ru) * 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
AR080328A1 (es) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20140350380A1 (en) * 2011-09-19 2014-11-27 The Feinstein Institute For Medical Research Identification and uses of brain activity networks
JP5404750B2 (ja) * 2011-11-22 2014-02-05 シャープ株式会社 認知症ケア支援方法、認知症情報出力装置、認知症ケア支援システム、及びコンピュータプログラム
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
US20160154928A1 (en) * 2013-07-12 2016-06-02 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
CA3125991A1 (en) * 2019-01-25 2020-07-30 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US20210002650A1 (en) * 2019-07-03 2021-01-07 University Of Virginia Patent Foundation Compositions and methods for treating alzheimer's disease
KR102271305B1 (ko) * 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
EP4190319A4 (en) 2020-07-29 2024-05-01 Novamedica Limited Liability Company PHARMACEUTICAL COMPOSITION CONTAINING MEMANTINE AND CITICOLINE
KR102272907B1 (ko) * 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2023248206A1 (en) * 2022-06-24 2023-12-28 Aribio Co., Ltd. Compositions and methods for preventing and treating neurodegenerative diseases
WO2024003784A1 (en) * 2022-06-29 2024-01-04 Aribio Co., Ltd. Composition for preventing and treating neurodegenerative diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (ru) * 1972-04-20 1973-10-23
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE58905637D1 (de) * 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
PT1009732E (pt) * 1997-06-30 2003-10-31 Merz & Co Gmbh & Co 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
SI1509232T1 (sl) * 2002-05-31 2009-04-30 Lundbeck & Co As H Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS

Also Published As

Publication number Publication date
NZ548327A (en) 2009-06-26
CA2551689A1 (en) 2005-07-28
PL1703902T3 (pl) 2011-04-29
DE602005024511D1 (de) 2010-12-16
RS51540B (en) 2011-06-30
US20100048726A1 (en) 2010-02-25
EP1703902A2 (en) 2006-09-27
WO2005067908A2 (en) 2005-07-28
US20060020042A1 (en) 2006-01-26
RU2371173C2 (ru) 2009-10-27
WO2005067908A3 (en) 2005-11-10
SI1703902T1 (sl) 2011-02-28
RU2007129842A (ru) 2009-02-10
AU2005204358A1 (en) 2005-07-28
IL176689A0 (en) 2006-10-31
CY1111359T1 (el) 2015-08-05
AU2005204358B2 (en) 2008-09-04
PT1703902E (pt) 2010-11-17
DK1703902T3 (da) 2011-02-14
ATE486592T1 (de) 2010-11-15
EP1703902B1 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
HRP20110035T1 (hr) Memantin za liječenje blage-do-umjerene alzheimer-ove bolesti
JP2021107401A (ja) カンナビノイドとｎ−アシルエタノールアミンの組み合わせ
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
BR0316753A (pt) Método de tratamento para disfunção sexual
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
EA201300314A1 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
NZ599082A (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
DE60106026D1 (de) 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
JP2016505050A5 (ru)
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
FI3634396T3 (fi) Koostumus L-DOPA-hoidon tehon parantamiseen
KR102195761B1 (ko) 아포에쿼린-함유 조성물을 기반으로 하는 다발성 경화증의 증상을 완화시키는 방법
RU2325146C1 (ru) Способ реабилитации больных рассеянным склерозом с нарушениями двигательных функций
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele